SBFM (Sunshine Biopharma) Cyclically Adjusted FCF per Share: $-3,176.67 (As of Mar. 2026)


SBFM Sunshine Biopharma Inc SBFM
34 GF Score
Price $2.12
GF Value $7.23
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sunshine Biopharma Cyclically Adjusted FCF per Share?

Sunshine Biopharma SBFM -2.34% 34 Cyclically Adjusted FCF per Share is $-3,176.67 as of Mar. 2026. GuruFocus rates SBFM with a GF Score™ of 34/100 and a GF Value™ of $7.23 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Sunshine Biopharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-4.434. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-3,176.67 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 14.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Sunshine Biopharma was 14.20% per year. The lowest was 14.20% per year. And the median was 14.20% per year.

As of today (2026-07-12), Sunshine Biopharma's current stock price is $2.12. Sunshine Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-3,176.67. Sunshine Biopharma's Cyclically Adjusted Price-to-FCF of today is .


Sunshine Biopharma  (NAS:SBFM) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Sunshine Biopharma Cyclically Adjusted FCF per Share Related Terms


Sunshine Biopharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Sunshine Biopharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Biopharma Cyclically Adjusted FCF per Share Chart

Sunshine Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -5,261.20 -5,875.93 -4,408.89 -3,324.09

Sunshine Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,097.54 -3,816.27 -3,568.76 -3,324.09 -3,176.67

SBFM vs PRFX, CTTH, CVSI: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Biopharma Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's Cyclically Adjusted Price-to-FCF falls into.


SBFM
34GF Score
Sunshine Biopharma Inc SBFM
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunshine Biopharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sunshine Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-4.434/330.2130*330.2130
=-4.434

Current CPI (Mar. 2026) = 330.2130.

Sunshine Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.000 251.989 0.000
201809 0.000 252.439 0.000
201812 0.000 251.233 0.000
201903 0.000 254.202 0.000
201906 0.000 256.143 0.000
201909 0.000 256.759 0.000
201912 0.000 256.974 0.000
202003 0.000 258.115 0.000
202006 0.000 257.797 0.000
202009 0.000 260.280 0.000
202012 0.000 260.474 0.000
202103 0.000 264.877 0.000
202106 0.000 271.696 0.000
202109 0.000 274.310 0.000
202112 0.000 278.802 0.000
202203 0.000 287.504 0.000
202206 -574.000 296.311 -639.673
202209 -1,124.000 296.808 -1,250.503
202212 -2,247.000 296.797 -2,499.987
202303 -2,028.000 301.836 -2,218.662
202306 -678.667 305.109 -734.507
202309 -469.000 307.789 -503.169
202312 -2,994.000 306.746 -3,223.050
202403 -1,295.000 312.332 -1,369.139
202406 -206.000 314.175 -216.516
202409 -15.488 315.301 -16.220
202412 -13.578 315.605 -14.206
202503 -7.063 319.799 -7.293
202506 -4.093 322.561 -4.190
202509 -1.671 324.800 -1.699
202512 -3.373 324.054 -3.437
202603 -4.434 330.213 -4.434

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-3,176.67 mean?
Sunshine Biopharma (SBFM) has a Cyclically Adjusted FCF per Share of $-3,176.67 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sunshine Biopharma and its competitors.
Is Sunshine Biopharma's Cyclically Adjusted FCF per Share too high?
Sunshine Biopharma's current Cyclically Adjusted FCF per Share is $-3,176.67. Overall, Sunshine Biopharma has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's Cyclically Adjusted FCF per Share compare to PRFX and CTTH?
Sunshine Biopharma's Cyclically Adjusted FCF per Share of $-3,176.67 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sunshine Biopharma and its competitors. Sunshine Biopharma's current Cyclically Adjusted FCF per Share is $-3,176.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Biopharma (SBFM) is currently considered Possible Value Trap. The stock's GF Value™ is $7.23, compared to a current price of $2.12 — trading 70.7% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $-3,176.67. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Sunshine Biopharma (SBFM), the current Cyclically Adjusted FCF per Share is $-3,176.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunshine Biopharma (SBFM) Overvalued in 2026?

Based on GuruFocus' analysis, Sunshine Biopharma stock appears to be undervalued. The current stock price of $2.12 is trading 70.7% below its estimated GF Value™ of $7.23. GuruFocus considers Sunshine Biopharma to be Possible Value Trap.

Key valuation signals for SBFM:

  • Cyclically Adjusted FCF per Share: $-3,176.67
  • GF Value™: $7.23 vs. price of $2.12 (70.7% below fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the SBFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sunshine Biopharma Business Description

Address 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL, USA, 33301
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score

Get the complete analysis for SBFM

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.12
Price
$7.23
GF Value